ClinicalTrials.gov record
Completed Phase 1 Interventional

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

ClinicalTrials.gov ID: NCT00085358

Public ClinicalTrials.gov record NCT00085358. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Study identification

NCT ID
NCT00085358
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
40 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Apr 30, 2011
Completion
Not listed
Last update posted
Jul 21, 2019

Started 2004

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
University of California Medical Center At Irvine-Orange Campus Orange California 92868
Colorado Gynecologic Oncology Group Aurora Colorado 80010
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637-1470
University of Iowa Hospitals and Clinics Iowa City Iowa 52242
Greater Baltimore Medical Center Baltimore Maryland 21204
Johns Hopkins University Baltimore Maryland 21287-8936
Washington University School of Medicine St Louis Missouri 63110
Cooper Hospital University Medical Center Camden New Jersey 08103
Case Western Reserve University Cleveland Ohio 44106
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland Ohio 44111
Lake University Ireland Cancer Center Mentor Ohio 44060
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104
Cancer Care Associates-Midtown Tulsa Oklahoma 74104
Cancer Care Associates-Yale Tulsa Oklahoma 74136-1929
Gynecologic Oncology Group Philadelphia Pennsylvania 19103
Women and Infants Hospital Providence Rhode Island 02905

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00085358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2019 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00085358 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →